恶性脑肿瘤的药物投递策略  

Drug delivery strategy for malignant brain tumors

作　　者：李涛[1] 张辰[1] 林雨[1] 于胜平 明浩朗[1] 任炳成[1] 马海文 张恺[2] 杨学军[1] Li Tao;Zhang Chen;Lin Yu;Yu Shengping;Ming Haolang;Ren Bingcheng;Ma Haiwen;Zhang Kai;Yang Xuejun(Department of Neurosurgery,Tianjin Medical University General Hospital,Tianjin 300052,China;Department of Surgery,the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China)

机构地区：[1]天津医科大学总医院神经外科,天津300052 [2]天津中医药大学第一附属医院外科,天津300193

出　　处：《中华脑科疾病与康复杂志（电子版）》2020年第4期225-229,共5页Chinese Journal of Brain Diseases and Rehabilitation（Electronic Edition）

摘　　要：恶性胶质瘤是人类最致命的肿瘤之一,尽管目前手术、放射治疗、化学治疗等治疗方式都取得了进展,但是预后不佳。一些恶性胶质瘤的新型化学药物在实验研究研究中效果明显,但临床疗效却大打折扣,因此,恶性脑肿瘤的药物投递方式也需同步发展。本文围绕恶性脑肿瘤的药物投递限制和策略作一综述。Malignant glioma is one of the most lethal tumors in human beings.Although surgery,radiotherapy and chemotherapy have made progress,the prognosis is poor.Some new chemical drugs of malignant glioma have obvious effect in experimental research,but the clinical effect is greatly reduced.Therefore,the drug delivery mode of malignant brain tumor also needs to be developed simultaneously.This review focuses on the drug delivery limitations and strategies for malignant brain tumors.

关 键 词：脑肿瘤 药物投递 血-脑屏障 

分 类 号：R739.41[医药卫生—肿瘤]